Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738140 | 0.91 | KCNH2 (0.52) | TSHRSMN1; SMN2GPBAR1CYSLTR1HTR1A | |
| SCHEMBL10602833 | 0.89 | TSHR (0.54) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 | |
| SCHEMBL16902876 | 0.89 | TSHR (0.54) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 | |
| SCHEMBL16902899 | 0.87 | TSHR (0.53) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 | |
| SCHEMBL16902896 | 0.87 | TSHR (0.53) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 | |
| SCHEMBL7254533 | 0.87 | TSHR (0.53) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 | |
| SCHEMBL16902884 | 0.87 | TSHR (0.53) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 | |
| SCHEMBL16902882 | 0.87 | TSHR (0.53) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 | |
| SCHEMBL16902887 | 0.87 | TSHR (0.53) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 | |
| SCHEMBL16902889 | 0.87 | TSHR (0.53) | TSHRSMN1; SMN2GPBAR1CYSLTR1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| CN-113754589-B | Compositions, methods, and systems for synthesizing and using contrast agents | 蓝瑟斯医学影像公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240100199-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-113754589-A | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-107311935-B | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2882719-A2 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014026079-A2 | COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | TSHR 3416/4885SMN1; SMN2 420/4885GPBAR1 1266/4885 |
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | TSHR 3187/4885SMN1; SMN2 699/4885GPBAR1 1044/4885 |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | TSHR 3416/4885SMN1; SMN2 420/4885GPBAR1 1266/4885 |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | TSHR 3187/4885SMN1; SMN2 699/4885GPBAR1 1044/4885 |
| US-20240100199-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | TSHR 3187/4885SMN1; SMN2 699/4885GPBAR1 1044/4885 |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | TSHR 3187/4885SMN1; SMN2 699/4885GPBAR1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.